News MSAA Publishes 2015 MS Research Updates for Multiple Sclerosis Management MSAA Publishes 2015 MS Research Updates for Multiple Sclerosis Management by Patricia Silva, PhD | May 6, 2015 Share this article: Share article via email Copy article link The Multiple Sclerosis Association of America (MSAA) recently publishedĀ the latest MS Research Update both printed and online atĀ mymsaa.org. This update is a comprehensive overview ofĀ research findings on FDA-approved disease-modifying therapies, as well as many experimental treatments for relapsing forms of multiple sclerosis (MS). In the publication, the authors also provide directions for potential new research. The information provided is based on a wide range of sources, including extensive journal literature on MS and its management, a review of ongoing clinical trials and papers presented at major national as well as international conferences. These include the 2014 conferences hosted by the American Academy of Neurology (AAN), the Consortium of Multiple Sclerosis Centers (CMSC), and the American and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS and ECTRIMS). The 2015 MS Research UpdateĀ includes fresh evidence about approved disease-modifying therapies (DMTs), and also many experimental drug agents that are now beingĀ tested as long-term treatments for multiple sclerosis (MS). Specifically, in the new edition the authors provide information about the recent approval of LEMTRADAĀ® by the FDA for relapsing types of MS, and also label changes the administration introducedĀ for TECFIDERAā¢. Along withĀ new updates targeting relapsing forms of MS, the MSAA provides updates on current researchĀ looking for treatments forĀ progressive forms ofĀ the disease. Importantly, theĀ 2015 MS Research UpdateĀ provides information on recent studies in different fields of research including therapies for myelin repair and protection, stem-cell research, genetic studies, biomarkers, among others, offering several and more complex treatment options for both healthcare professionals and patients. BecauseĀ patient awareness and education is vital for an effective management of MS, the 2015 Research Update,Ā along withĀ other MSAA resources, are valuableĀ tools for thoseĀ looking for information concerningĀ MS treatment options. More information can be found in the MSAA website at mymsaa.org. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags multiple sclerosis, Multiple Sclerosis Association of America
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study